Staar Surgical Company · NASDAQ:STAA
Staar Surgical — ASCRS Investor Breakfast 2011
34 slides from Staar Surgical's conference presentation, Mar 28, 2011
Slide 1: Refractive ICLs Investor Breakfast
(NASDAQ: STAA) Refractive ICLs Investor Breakfast ASCRS Ss % March 26, 2011
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS All statements in this presentation that are not statements of historical fact are forward-looking statements, including any projections of camings, revenue, profit margin, cash or other financial items, any statements of the plans, strategies, and objectives of management
Slide 3: Agenda
AGENDA = Introductions = Visian ICL Enhancement Progress = FDA Update on Toric ICL = V4b and V4c = Update on Japan Business Impacts = 2011 Key Metrics = Question and Answets
Slide 4: Visian ICL Product Pipeline
Visian ICL Product Pipeline Lower myopes and toric hyperopic V4c Eliminates need for PI V5 Preloaded, enhanced safety design
Slide 5: Toric ICL Under Review by FDA
Toric ICL Under Review by FDA U.S. FDA under current review . = Major Response to FDA on December 234 . Current discussions have centered on the old data base vetsus the audited data base Still can approve, send to panel or not approve
Slide 6: V4b ICL CE Mark Approval
V4b ICL CE Mark Approval Launched During Q4 2010 . = Can be used as LASIK enhancement In Europe refractive surgeons do not need an excimer laser
Slide 7: V4b Rollout Progress
V4b Rollout Progtess = 19 of 25 approved markets have started to implement product = 74% of ICL sales in those 25 markets = 9 markets are 90% or greater = Through 11 weeks of QI = Increase of 6% in units where implemented due to the extended range of product =™8% increase on the Toric ICL side
Slide 8: V4c ICL Design
V4c ICL Design 360 micron hole in center of ICL Enhances flow within the eye Believe it eliminates the need for iridotomy /itidectomy Makes procedure much more convenient for the patient and surgeon (LASIK-like)
Slide 9: Status of the V4c Product
Status of the V4c Product + Product has been Verified and Validated + Product has been clinically tested + Submitted to our notified body for CE Mark 3 series of questions answered Anticipate CE Mark recommended approval in next two weeks. - CE Mark should be given within four weeks from recommendat
Slide 10: V4c Clinical Experience
V4c Clinical Experience First Phase study in 2008 (Dr. Shimizu in Japan) : 6 patients implanted with standard ICL in one eye and modified ICL in fellow eye. + Tri ies created in eyes iving standard ICL. + No itidotomies in eyes with V4c. Second Phase study in 2010 (Dr. Shimizu) - 19 patients — repea
Slide 11: Post Op Uncorrected Visual Acuity
Post Op Uncotrected Visual Acuity —®—Hole normal
Slide 12: Contrast Sensitivity
Contrast Sensitivity vac (Game) 0.18 0.48 0.78 1.08 1.26 0.18 0.48 0.78 1.08 1.26 Log spatial frequency(cycle/degree) Log spatial frequency(cycle/degree)
Slide 13: Operation time in Minutes
Operation time in Minutes 32% less time to perform x
Slide 14: Intraocular Pressure (IOP)
Intraocular Pressure (IOP) No difference in clinical results w/o hole (mmHg) —@Hole normal
Slide 15: Summarize Clinical Data
Summarize Clinical Data From Dr. Shimizu = Clinical data reflects no difference in key visual measutes: = Post Op Uncorrected Visual Acuity = Post Op Best Corrected Visual Acuity = Predictability of Outcomes = Stability of Refraction = Contrast Sensitivity = Flare = Intraocular Pressures (IOP)
Slide 16: STAAR Proprietary Position
STAAR Proprietary Position Two patents with claims related to a central hole in ICL to provide fluid flow US. Patent 5,480,428 (April 2014) = Specific function of the hole to eliminate need for itidotomies. U.S. Patent 5,913,898 (October 2014) Pursuing potentially additional opportunities to protect
Slide 17: What we think the V4c means
What we think the V4c means = Will improve the safety profile for the ICL = Increase the efficiency for the physician and staff = Reduce the discomfort for the patient and make it more convenient = May encourage existing customers to use the ICL in lower diopter ranges = Should enhance the positive
Slide 18: Slide 18
Slide 19: Visian ICL DTC Testing
Visian ICL DTC Testing = Movie Theater: STAAR Campaign, started March 18% = Pre-movie ads, shown before all movies for 4 weeks = 3 multiscreen theaters, LA, Phoenix, Houston = In-lobby promotions — consumer leaflets — surgeon and/or visianinfo = www.SeeGreatNow.com Cable TV: Co-op Campaign = Dr. Pau
Slide 20: Direct to Consumer Testing
Direct to Consumer Testing Cinema Program Location Ad / Focus Practices Century Clark Kent / | Dougherty, Boxer Wachler, Ci, LA | Glasses Maloney Best Day Ever / | BDPEC, SW Fye, Brems, Phoenix | Contacts Schwartz, Walman Marco Polo / Houston | Contacts Wade, Slade Exposure: 313,000 movie goers over
Slide 21: Movie Theater Testing
Movie Theater Testing Television monitors running the ads Print Coupon Patient specific ~ name on coupon
Slide 22: First Week Results
First Week Results = Google Analytics Reports daily = First week results = 125 visitors to the website = 75 direct to the website = 25 redirected from Facebook = 25 redirected from other websites = 83% from the U.S. = Test, evaluate, improve phase
Slide 23: NSPE Dele ARI BRA
A 24 NSPE Dele ARI BRA Ire = 2 E- eo: = =} Ire on AR
Slide 24: New Advertisement 2011
New Advertisement 2011 New Advertising Copy Why Is the ICL than Laser surgery? SF srr ( (Gaeta
Slide 25: New Advertisement 2011
New Advertisement 2011 [ Bus Side Ad * 100 buses throughout downtown area in Seoul Sern | * Advertisements on the side of buses
Slide 26: New Advertisement 2011
New Advertisement 2011 HQ? pesse (my — aic.e a) 7 > SS ar 7 Cessna a Y7sran
Slide 27: New Advertisement 2011
New Advertisement 2011 Continuity [ ‘Commercials in Movie Theater In Colege Lecture ey ‘a ret) tis because the stable vision is ‘most important after surgery. whys the IC expensive than laser refractive ° surgery? Exch [CLs custom made to meet the needs ofeach individual eve ‘Why the ICL much more s
Slide 28: Slide 28
Slide 29: Distribution Map of East and West
Distribution Map of East and West Japan Sales Department East is 51% of sales in SJ. * Tohoku area is 6.2% of sales in SJ.
Slide 30: STAAR Japan
STAAR Japan 100% of employees are safe and have been REAL CHAMPIONS Some had to stay in our Tokyo facilities Friday and Saturday (earthquake on Friday) Orders are being taken by customer service daily Jp and running by Monday afternoon Manufacturing is fully operational (up and running on Wednesday)
Slide 31: STAAR Japan
STAAR Japan = Sales during week 11 and 12 have been above the levels for the first 10 weeks of the quarter = See no impact on the quarter = The vast majority of our sales in Japan are IOLs though we are counting on strong growth in ICL during 2011 = Impact on refractive procedures for the year? = At
Slide 32: 2011 Key Metric Report Card
2011 Key Metric Report Card Double Digit Revenue Growth Grow ICL Sales by 25% Continuous Expansion of GM %, End year at 66% Profitable in 3 of 4 quarters and for the full year
Slide 33: Questions and Answers
Question and Answets
Slide 34: Refractive ICLs Investor Breakfast
(NASDAQ: STAA) Refractive ICLs Investor Breakfast ASCRS Ss % March 26, 2011